Clinical Trial Update: PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating PEG-Interferon alfa-2b in patients with metastatic kidney cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• PEG-Interferon alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED